Gulfo Might Reevaluate Negotiated User Fees If Selected US FDA Commish

Joseph Gulfo, a former medtech industry CEO and vocal FDA critic, is the latest candidate apparently being considered for FDA commissioner. In an interview with Medtech Insight, he outlines his worldview and interest in pushing aggressively against increasing the FDA "body of law."

Another candidate has hopped into the running as the potential next US FDA commissioner: Joseph Gulfo. In an interview with Medtech Insight, the former medical diagnostic industry executive and author says he would take a closer look at the recently negotiated user-fee agreements between FDA and medical-product industries to find ways to cut any unnecessary regulations and legal overreach.

Gulfo is the fourth potential Trump administration FDA commissioner candidate to make it into public view. The others include Jim...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Regulation

Scores Of Companies On Board With Medicare Data Interoperability And Digital Health Initiative

 

The Centers for Medicare and Medicaid Services has launched a new program the agency says will allow patients easier access to their health data. More than 60 companies have already signed on.

Why EU Notified Bodies Need To Alter The Way They Work

 

Without change, the implementation of the MDR and IVDR could hit another wall.

J&J MedTech’s Digital Head Pushes for Smarter, Standardized ORs With AI and Open Tech

 
• By 

J&J’s global head of MedTech Digital envisions AI-powered connected operating suites within a decade. In an interview with Medtech Insight, Shan Jegatheeswaran discusses how J&J, together with partners like NVIDIA and AWS, is laying the foundation for open platforms for standardized surgeries.

Roberts’ Departure At NICE Sparks Hunt For New CEO

 
• By 

Healthtechs are reflecting on the resignation of Sam Roberts as chief executive of NICE and how medtech assessment program changes underway at the England and Wales HTA body might be impacted.

More from Policy & Regulation

Why EU Notified Bodies Need To Alter The Way They Work

 

Without change, the implementation of the MDR and IVDR could hit another wall.

UK MHRA Takes Stock, Seeks CMSO And Reveals Device Innovation Early Access Thinking

 
• By 

Evolution of the MHRA and its offering to medtechs continues, with the hunt for a visionary chief medical and scientific officer and release of outline plans on early access to innovative devices, building on IDAP learnings.

US FDA Webinar Highlights 506J Expectations Amid Ongoing Supply Chain Vulnerabilities

 
• By 

A recent CDRH Learn module urges medical device manufacturers to report potential shortages early, even outside emergencies, to help prevent disruptions. Recent natural disasters underscore the need for resilient supply chains, and reported shortages may be added to an FDA list.